239 related articles for article (PubMed ID: 31965178)
1. Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B.
van de Peppel RJ; Schauwvlieghe A; Van Daele R; Spriet I; Van't Wout JW; Brüggemann RJ; Rijnders BJA; Hendriks BJC; de Boer MGJ
Med Mycol; 2020 Oct; 58(7):874-880. PubMed ID: 31965178
[TBL] [Abstract][Full Text] [Related]
2. New pharmacological opportunities for the treatment of invasive mould diseases.
Ledoux MP; Toussaint E; Denis J; Herbrecht R
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
4. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a clinical decision rule for selecting empiric treatment for invasive aspergillosis in a setting with high triazole resistance.
van de Peppel RJ; van Grootveld R; Hendriks BJC; van Paassen J; Bernards S; Jolink H; Koopmans JG; von dem Borne PA; van der Beek MT; de Boer MGJ
Med Mycol; 2021 Dec; 60(1):. PubMed ID: 34878121
[TBL] [Abstract][Full Text] [Related]
6. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
[TBL] [Abstract][Full Text] [Related]
7. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013.
Chen CY; Sheng WH; Tien FM; Lee PC; Huang SY; Tang JL; Tsay W; Tien HF; Hsueh PR
J Microbiol Immunol Infect; 2020 Feb; 53(1):106-114. PubMed ID: 29449166
[TBL] [Abstract][Full Text] [Related]
12. Case reports. Invasive pulmonary aspergillosis in non-neutropenic patients treated with liposomal amphotericin B.
Zhirong Y; Wanqing L; Weihua P
Mycoses; 1999; 42(11-12):679-82. PubMed ID: 10680448
[TBL] [Abstract][Full Text] [Related]
13. [Mixed invasive fungal infection due to Rhizomucor pusillus and Aspergillus niger in an immunocompetent patient].
Pozo-Laderas JC; Pontes-Moreno A; Robles-Arista JC; Bautista-Rodriguez MD; Candau-Alvarez A; Caro-Cuenca MT; Linares-Sicilia MJ
Rev Iberoam Micol; 2015; 32(1):46-50. PubMed ID: 23583263
[TBL] [Abstract][Full Text] [Related]
14. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
[TBL] [Abstract][Full Text] [Related]
15. Successful management of pulmonary mucormycosis with liposomal amphotericin B and surgery treatment: a case report.
Serio B; Rosamilio R; Giudice V; Zeppa P; Esposito S; Fontana R; Annunziata S; Selleri C
Infez Med; 2012; 20 Suppl 2():43-7. PubMed ID: 23042005
[TBL] [Abstract][Full Text] [Related]
16. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
17. Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B.
Erbey F; Kocabaş E; Bayram İ; Soyupak S; Gümürdülü D; Tanyeli A
Tuberk Toraks; 2012; 60(4):375-9. PubMed ID: 23289469
[TBL] [Abstract][Full Text] [Related]
18. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
20. Can intravenous antifungal therapy be safely used in the outpatient parenteral antimicrobial therapy (OPAT) setting?
Rae N; Kenny C; Muldoon EG
Mycoses; 2019 Mar; 62(3):196-203. PubMed ID: 30499620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
